Legend Biotech surges on early in vivo CAR-T data for lymphoma
Decision brief
Answer first · skim in under a minute
Legend Biotech's experimental in vivo CAR-T therapy, LB2501, reduced or eliminated disease signs in all treated lymphoma patients in a first-in-human trial. The data fuel hopes that the approach could compete with ex vivo therapies like Novartis' Kymriah.
Legend Biotech reported first clinical proof-of-concept for LB2501, an in vivo CD19/CD20 dual-target CAR-T, with a 100% objective response rate at dose level 2 in relapsed/refractory B-cell non-Hodgkin lymphoma — early data that invite comparison with ex vivo products such as Novartis’s Kymriah.
Contents8 sections
Key Takeaways
- At EHA 2026, Legend said LB2501 achieved 100% ORR (6/6) and 83.3% CR (5/6) at dose level 2 without lymphodepletion.
- Across both dose levels (n=12), ORR was 50.0% and CR 41.7%; all DL2 responses were ongoing at data cutoff.
- No DLTs, SAEs, ICANS, or deaths were reported in the Phase 1 disclosure.
- The study is registered as NCT07002112 on ClinicalTrials.gov; durability versus approved ex vivo CAR-T products remains unproven.
What did Legend announce for LB2501?
Legend Biotech’s June 14, 2026 GlobeNewswire release detailed late-breaking EHA 2026 data (Abstract LB5006) for LB2501 in relapsed or refractory B-cell non-Hodgkin lymphoma.
A single infusion generated dose-dependent in vivo CAR-T expansion without lymphodepletion. At the higher dose level (DL2), ORR was 100% (6/6) and complete response 83.3% (5/6), with responses across DLBCL, mantle cell lymphoma, and follicular lymphoma.
Across DL1 and DL2 combined, ORR was 50.0% (6/12) and CR 41.7% (5/12). Legend reported no dose-limiting toxicities, serious adverse events, ICANS, or deaths in the disclosed safety set.
How does in vivo CAR-T differ from ex vivo products like Kymriah?
Approved autologous products such as Kymriah (tisagenlecleucel) require leukapheresis, ex vivo manufacturing, and typically lymphodepleting chemotherapy before infusion.
LB2501 is designed as an in vivo lentiviral approach that engineers T cells inside the patient after infusion, aiming to cut vein-to-vein time and manufacturing complexity.
That architectural difference is why early ORR headlines move Legend’s stock narrative. It is not evidence that LB2501 matches Kymriah’s labeled indications, long-term survival data, or manufacturing scale.
What trial is generating the data?
The Phase 1 first-in-human study is listed on ClinicalTrials.gov as NCT07002112 for the CD19/CD20 dual-target in vivo CAR-T lentiviral product in relapsed/refractory B-cell malignancies.
Translational notes in Legend’s release say vector integrations were polyclonal and that non-specific transduction was not detected in NK or other non-T/B/NK lymphocyte populations — supportive biology for the platform thesis, still early.
Median follow-up for ongoing DL2 responses was measured in months at cutoff, not years. Durability and larger-dose cohorts will decide whether the 100% DL2 ORR holds.
What remains unproven versus Kymriah-class therapy?
n=6 at DL2 is a proof-of-concept cell, not a registrational dataset. Cross-trial comparisons to Kymriah or other CD19 CAR-T products are inappropriate without matched populations and follow-up.
Manufacturing cost, redosing, insertional oncogenesis risk, and outpatient feasibility claims were not settled by the EHA late-breaker.
Related NovaPharma coverage
Frequently Asked Questions
What efficacy did Legend report for LB2501?
At dose level 2 in the Phase 1 study, Legend reported a 100% objective response rate (6/6) and an 83.3% complete response rate (5/6) in relapsed/refractory B-cell non-Hodgkin lymphoma, with all DL2 responses ongoing at data cutoff.
Was lymphodepletion required for LB2501?
Legend said a single infusion generated dose-dependent in vivo CAR-T expansion without lymphodepletion in the disclosed Phase 1 experience.
How does this relate to Kymriah?
Kymriah is an FDA-approved ex vivo autologous CAR-T. LB2501 is an investigational in vivo approach; early ORR data do not establish equivalence to Kymriah’s labeled outcomes.
Primary Sources
Regulatory catalyst tracker
Track PDUFA dates, approval milestones, and label updates for Kymriah.
Unlock full calendar →Legend Biotech pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Investor brief
Download a one-page summary of regulatory impact and competitive context.
Explore drug hub →Entity graph
Continue Exploring
Open the drugs, companies, and topics behind this story.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
